STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?
|
|
- Loraine Montgomery
- 6 years ago
- Views:
Transcription
1 STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? MICHAEL LANUTI, MD American Association of Thoracic Surgeons Minneapolis, MN 2013
2 STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY MICHAEL LANUTI, MD RADIOTHERAPY? American Association of Thoracic Surgeons Minneapolis, MN 2013
3 DISCLOSURES Financial None Device RF ablation in lung is considered off label 3
4 HIGH RISK STAGE I NSCLC TREATMENT ALTERNATIVES PERCUTANEOUS ABLATION RADIOFREQUENCY MICROWAVE CRYO Irreversible Electroporation (NanoKnife) STEREOTACTIC BODY RADIOTHERAPY (SABR) STEREOTACTIC ABLATIVE BODY RADIOTHERAPY SUBLOBAR PULMONARY RESECTION NO TREATMENT TIME (MO.) SURVIVAL % Raz D. et al., Chest
5 MODALITY BY ZONE FOR HIGH RISK STAGE I NSCLC PATIENTS Peripheral Zone: SBRT, Sublobar resection Ablation 5 Middle Zone: SBRT Sublobar resection +/- brachy Central Zone: IMRT, Proton SBRT Sublobar resection +/- brachy
6 MANAGEMENT OF STAGE I NSCLC 20-25% of NSCLC patients have stage I (T1/T2aN0) disease The gold standard for treatment of operable patients is surgical resection (anatomic resection segment vs lobe). For high-risk operable patients, typically due to compromised cardiopulmonary function, alternative surgical strategies (such as wedge resection, wedge + brachytherapy, segmentectomy) have been utilized. About 20-30% of patients are medically inoperable and need non-surgical therapy. 6
7 79yo smoker with symptomatic neurovascular disease, ECOG PS=2, DLCO=28% What treatment option would you offer? 7
8 RADIOFREQUENCY ABLATION BACKGROUND Radiofrequency Ablation (RFA) is a local ablative treatment for tumors Lung Application: 2000 Single institution case series Phase I/II study (ACOSOG Z4033) closed to accrual, 2-yr outcomes of high risk patients with stage IA 8
9 EXPECTED CT FINDINGS 1 year later 9 months later 6 months later 3 months later 1month later Before RF ablation 9
10 ELECTRODES Single, cluster or multi-tined array Uninsulated tip Temperature or Impedance based Covidien (Valley Lab) Angiodynamics (RITA) Boston Scientific
11 AUTHOR N AGE ABLATION MEAN TECHNOLOGY SIZE (CM) Beland Covidien 2.5 Stage I 79 ( ) Choe Stage I (20) 3 Lanuti 2009 Stage I REVIEW OF LITERAURE RFA TREATMENT OF STAGE I NSCLC Covidien 4.2 ± ± 1.2 Cryo 70 Covidien 2.0 ± 1.0 ( ) LOCAL DEATHS MED F/U OVERALL RECURRENCE (MO.) SURVIVAL 34/79 (43%) mo (DFS) 24% 14% yr 46% 3-yr 27% 12/38 (31%) 0 17±11 2-yr 78% 3-yr 47% 2-yr DFS 57% Lancioni Stage I 13 Hiraki Stage I 20 Pennathur Stage I 19 Simon Stage I 75 Sano Stage I 30 Dupuy Stage I 24 Fernando Stage I 9 Greico Stage I RITA 2.2 ± 1.6 3/ yr 48% 2-yr 75% Cancer sp 2-yr 92% 76 LeVeen Covidien 78 LeVeen RITA 69 Covidien 2.4 ( ) 7/20 (35%) yr 84% 3-yr 74% Cancer sp 93%, 83% 2.6 ( ) 8/19 (42%) yr 68% 3.0 ( ) NR yr 57% 3-yr 36% 4-yr 27% 63 Covidien LeVeen 2.1 ( ) NR 2* NR NR 76 Covidien 3.4 ( ) 2/24 (8.3%) yr 50% followed by XRT Met dz 9 75 LeVeen 2.8 ( ) 8/21 (38%) 1 14? Covidien Microwave? 12% < 3cm 33% > 3cm 17.6 mo (PFS) yr 70%
12 RFA TREATED STAGE I NSCLC N = 45 patients (55 ablations) RTOG 0236 Median survival = 44.3 mo (48 mo.) 3-Yr survival = 67% (55%) 5-Yr survival = 31% Patients at risk Lanuti M et al. Ann Thorac Surg, 2012 Mar;93(3):921-8
13 LOCOREGIONAL RECURRENCE SIZE THRESHOLD TUMOR SIZE (CM) # LESIONS % LOCOREGIONAL RECURRENCE < % > % 13 Lanuti M et al. Ann Thorac Surg, 2012 Mar;93(3):921-8
14 TUMOR SIZE IN ALL PATIENTS N = 45 patients Median surv. = 59 mo. Median surv. = 29 mo. Patients at risk TUMOR > 3 CM TUMOR < 3 CM Lanuti M et al. Ann Thorac Surg, 2012 Mar;93(3):921-8
15 RADIOFREQUENCY ABLATION LIMITATIONS Large size (> 3cm) Proximity to bronchovascular structures, esophagus, or trachea Regional nodal disease Most frequent complications are pneumothorax (16-54%) and pleural effusion (~19%) 15
16 FAILURE PATTERN AFTER INITIAL RFA 22% (8-43%) LOCAL FAILURE: re-growth in the ablated tumor bed or involved lobe REGIONAL FAILURE: ipsilateral hilar or mediastinal failure 7-25% DISTANT FAILURE: uninvolved lobe and extrathoracic sites NR 16
17 HIGH RISK STAGE I NSCLC TREATMENT ALTERNATIVES RADIOFREQUENCY ABLATION STEREOTACTIC BODY RADIOTHERAPY 17
18 79yo smoker, COPD, CAD, PVD, previous RUL, RLL lung cancer 2 Years Later Nov 2010: SBRT 4 x 12 Gy 18
19 19 TRADITIONAL APPROACH
20 WHAT IS STEREOTACTIC BODY RADIATION THERAPY (SBRT)? SBRT delivers tumor ablative doses with high precision in shorter time SBRT has unique biological characteristics high rates of tumor control. There are multiple, roughly equivalent treatment methods, often called by the brand names of the manufacturers, such as Axesse, CyberKnife, Novalis, Primatom, Synergy, True beam, TomoTherapy, or Trilogy. Proton beam is also being investigated with SBRT* *Westover K, et al. Proton Stereotactic Body Radiation Therapy for Medically Inoperable Stage I NSCLC. J Thor Onc
21 SBRT - INDICATIONS SBRT is rapidly replacing conventional radiation and offers therapy to patients who previously had no good treatment options NCCN Guidelines 2012 for use of SBRT: Medically inoperable N0 status Primary < 5 cm Peripheral location Zone of proximal bronchial tree 21
22 SBRT TREATMENT DOSE AND IMMOBILIZATION TECHNIQUE Dose prescription for peripheral tumors: Standard: 18 Gy x 3 = 54 Gy over ~10 days Alternatives: 12 Gy x 4 = 48 Gy or 10 Gy x 5 = 50 Gy Meticulous normal tissue sparing (esophagus, chest wall) Non-invasive immobilization +/- vacuum + abdominal compression 22
23 SBRT FOR MEDICALLY INOPERABLE STAGE I CLINCIAL TRIALS Baumann et al. 2009, JCO 27, 3290; Bradley et al. 2009, IJROBP Sept 30 Epub; Fakiris et al. 2009, IJROBP 76, 677; ; Grills et al. 2010, JCO 28, 928; Nagata et al. 2005, IJROBP 63, 1427; Timmerman et al. 2010, JAMA 303,
24 SIDE EFFECTS Grade 1-2 reactions: fatigue, rash, radiographic pneumonitis (common, self limited) Grade 3+ toxicity (pulmonary, musculoskeletal) is uncommon (5-10%) No mortality for peripheral tumors Fatal complications have been reported in cases with centrally located tumors (near major bronchus, heart, major blood vessels, trachea) treated to high doses (3 x 20 Gy) gentler fractionation schemes are being explored, such as 5 x Gy (RTOG 0813) 24
25 FAILURE PATTERN AFTER SBRT LOCAL FAILURE: re-growth in the ablated tumor bed or involved lobe 10% REGIONAL FAILURE: ipsilateral hilar or mediastinal failure 5-10% DISTANT FAILURE: uninvolved lobe and extrathoracic sites 22% 25
26 RFA vs. SBRT FOR STAGE I NSCLC Comparison RFA (Chan VO, 2011) SBRT (Onishi H, 2007) SBRT RTOG 0236 (Timmerman R 2010) Number Patients Local recurrence 22.2% 14-16% 9.6% Regional nodal recurrence NR 10-13% 4% 3-yr OS, (DFS) 65% 57% (77%) 56% (48%) 5-yr OS, (DFS) 58% (82%) 47% (73%) NR Median follow up 90 months 38 months 34 months Review of 21 studies (8) examining RFA in stage I NSCLC Chan et al. J Thorac Imaging Multi-institutional Japanese study, Onishi et al. J Thor Oncol, RTOG 0236 Timmerman et al. JAMA,
27 RADIOFREQUENCY ABLATION SUMMARY RFA is reasonable treatment option in high risk stage I NSCLC patients with peripheral lesions < 3cm. There is no consensus on treatment duration or number of treatments. RFA may be considered for tumors > 3cm in combination with radiation therapy. There is no consensus on sequence of therapy. RFA is not indicated for lesions adjacent to major bronchovascular structures, or esophagus. RFA can be used to salvage tumor recurrence after SBRT 27
28 STEREOTACTIC BODY RADIATION THERAPY SUMMARY Despite lack of phase III trials, SBRT is the preferred treatment for medically inoperable patients with peripheral T1/2N0 (< 5 cm) NSCLC Treatment consists of 3-5 treatments delivering a total dose of Gy with various techniques available Local control is 80-95% at 3 years, nodal failures are < 10%. Toxicity for peripheral tumors is uncommon ~ 5-10% risk of grade 3+ side effects A modified SBRT treatment schedule is recommended for tumors within 2cm of the proximal bronchial tree SBRT for operable patients remains investigational 28
29 CONCLUSIONS Pulmonary resection is the preferred approach for early stage disease. Provides tissue for molecular profiling and lymph nodes for staging. As there exist several treatment options for medically inoperable or high risk patients with stage I NSCLC, including sublobar resection, SBRT, and RFA, an individual patient should be carefully evaluated by a multidisciplinary team to identify an approach that minimizes locoregional failure as well as treatment complications and preserve overall survival. 29
30 Q50. In a medically inoperable 78yo, what is your preferred strategy for a 2cm tumor centrally located in the RLL where the PET is negative in the mediastinum? a. Refer to SBRT b. RFA c. Refer for conventional fractionated radiation therapy d. Mediastinoscopy followed by referral to SBRT
31 31
32 RFA vs. SBRT FOR STAGE I NSCLC Scorecard RFA SBRT Peripheral Stage I NSCLC 3cm 5 cm Local recurrence 22.2% 9.6% Regional nodal recurrence 10-25% 4%-25% Preservation of Lung Function Good Good 3-yr OS, (DFS) 65% 56% (48%) 5-yr OS, (DFS) 58% (82%) NR 90-day mortality Low Low Cost (Sher DJ et al. Int J Radiat Oncol Biol Phys. 2011) $5879 $11,014 *More cost effective QALY 32
33 PROSPECTIVE TRIALS OF SBRT OPERABLE STAGE I NSCLC RTOG NCT Phase II, stage I, SBRT (18 Gy x 3) Accrual goal 33 pts, started 2007, closed 2010 ROSEL Netherlands - NCT Phase III, stage IA, anatomical resection vs SBRT (20 Gy x 3 or 12 Gy x 5); Accrual goal 960 pts, started 2008, to be completed in 2015 (terminated) STARS MDACC/Accuray - NCT Phase III, stage I (<4cm), lobectomy vs CyberKnife (20 Gy x 3, 15 Gy x 4) Accrual goal 1030 pts, started 2008, to be completed in 2013 (terminated) RTOG 1021 / ACOSOG - NCT Phase III, stage IA/IB, SBRT (18 Gy x 3) vs sublobar (+/- brachytherapy) Accrual goal 420 pts, started 2011 to be completed in
34 COMPARISON OF ADVERSE EVENTS OF PROSPECTIVE TRIALS 34 Crabtree T et al. JTCVS 2013; 145:
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationTherapy of Non-Operable early stage NSCLC
SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical
More informationStereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery
Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation I: Patient ER 74 y/o male with A1A
More informationSurgery versus stereotactic body radiation therapy in medically operable NSCLC
Surgery versus stereotactic body radiation therapy in medically operable NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke
More informationIs Resection Superior to SBRT for Stage I Lesions. Traves Crabtree MD Professor of Surgery Southern Illinois University School of Medicine
Is Resection Superior to SBRT for Stage I Lesions Traves Crabtree MD Professor of Surgery Southern Illinois University School of Medicine I have nothing pertinent to disclose. Patterns of Recurrence for
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationStereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer
Review Article Page 1 of 9 Stereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer Tomoki Kimura Department of Radiation Oncology, Hiroshima University Hospital,
More informationStereotactic ablative radiotherapy in early NSCLC and metastases
Stereotactic ablative radiotherapy in early NSCLC and metastases Scheduled: 0810-0830 hrs, 10 March 2012 Professor Suresh Senan Department of Radiation Oncology SABR in stage I NSCLC A major treatment
More informationThoracic Recurrences. Soft tissue recurrence
Stereotactic body radiotherapy for thoracic and soft malignancies Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationTecniche Radioterapiche U. Ricardi
Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationInterventional Management of NSCLC. Hiran C Fernando FRCS Professor and Chief, Division Thoracic Surgery Boston Medical Center
Interventional Management of NSCLC Hiran C Fernando FRCS Professor and Chief, Division Thoracic Surgery Boston Medical Center Comparison of MWA and RFA Qiang Lu et al; AATS 2015 141 patients; 100 with
More informationVATS Segmentectomy. Duke Masters Course Sept 2015
VATS Segmentectomy Duke Masters Course Sept 2015 Scott J. Swanson, M.D. Director, Minimally Invasive Thoracic Surgery Brigham and Women s Hospital Chief Surgical Officer Dana Farber Cancer Institute Professor
More informationOncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer
Oncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationLung Cancer Radiotherapy
Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think
More informationSBRT in early stage NSCLC
SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques
More informationResults of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance?
Results of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance? Frank Zimmermann Institute of Radiation Oncolgy University Clinic Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch
More information- In potentially operable patients -
Lung Stereotactic Ablative Radiotherapy (SABR) - In potentially operable patients - Frank Lagerwaard VUMC Amsterdam Stereotactic Ablative Radiotherapy (SABR) 2003-2008 4DCT-based target definition Non-gated
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationHistory of Surgery for Lung Cancer
Welcome to Master Class for Oncologists Session 1: 7:30 AM - 8:15 AM San Francisco, CA October 23, 2009 Innovations in The Surgical Treatment of Lung Cancer Speaker: Scott J. Swanson, MD 2 Presenter Disclosure
More informationNon small cell Lung Cancer
Non small cell Lung Cancer The 13th refresher course for residents in radiation oncology Jiraporn Setakornnukul, M.D. Radiation oncology division, Radiology department Siriraj Hospital, Mahidol University
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationNO ROLE FOR TUMOR ABLATION IN THE ERA OF STEREOTACTIC BODY RADIATION FOR STAGE I LUNG CANCER
NO ROLE FOR TUMOR ABLATION IN THE ERA OF STEREOTACTIC BODY RADIATION FOR STAGE I LUNG CANCER Bryan Meyers MD MPH Washington University School of Medicine THE PLAYERS Stereotactic body radiation therapy
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationSagar Damle, MD University of Colorado Denver May 23, 2011
Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationOncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer
Oncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes
More informationAccomplishes fundamental surgical tenets of R0 resection with systematic nodal staging for NSCLC Equivalent survival for Stage 1A disease
Segmentectomy Made Simple Matthew J. Schuchert and Rodney J. Landreneau Department of Cardiothoracic Surgery University of Pittsburgh Medical Center Financial Disclosures none Why Consider Anatomic Segmentectomy?
More informationRF Ablation: indication, technique and imaging follow-up
RF Ablation: indication, technique and imaging follow-up Trongtum Tongdee, M.D. Radiology Department, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Objective Basic knowledge
More informationAdvaMed Medtech Value Assessment Framework in Practice
AdvaMed Medtech Value Assessment Framework in Practice Application of the Medtech Value Assessment Framework to Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Value Framework Overview
More informationN.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic
More informationCase Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12
Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.
More informationIndications for sublobar resection for localized NSCLC
Indications for sublobar resection for localized NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke University School of Medicine
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationTHORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationRadiofrequency ablation for treatment of medically inoperable stage I non small cell lung cancer
EVOLVING TECHNOLOGY Radiofrequency ablation for treatment of medically inoperable stage I non small cell lung cancer Michael Lanuti, MD, a Amita Sharma, MD, b Subba R. Digumarthy, MD, b Cameron D. Wright,
More informationPercutaneous radiofrequency ablation of clinical stage I non small cell lung cancer
GENERAL THORACIC SURGERY Percutaneous radiofrequency ablation of clinical stage I non small cell lung cancer Takao Hiraki, MD, a Hideo Gobara, MD, a Hidefumi Mimura, MD, a Yusuke Matsui, MD, a Shinichi
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationRadiotherapy What are our options and what is on the horizon. Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology
Radiotherapy What are our options and what is on the horizon Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology Outline Advances in radiotherapy technique Oligo - disease Advancements
More informationStereotactic Ablative Radiotherapy for Non Small Cell Lung Cancer: Rationale and Outcomes
1514 Original Article Stereotactic Ablative Radiotherapy for Non Small Cell Lung Cancer: Rationale and Outcomes Puneeth Iyengar, MD, PhD, a and Robert D. Timmerman, MD a,b Abstract Stereotactic ablative
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationSTEREOTACTIC BODY RADIATION THERAPY FOR THE TREATMENT OF EARLY STAGE NON SMALL CELL LUNG CANCER
STEREOTACTIC BODY RADIATION THERAPY FOR THE TREATMENT OF EARLY STAGE NON SMALL CELL LUNG CANCER A Technology Assessment INTRODUCTION The California Technology Assessment Forum was requested to review the
More informationCT guided thermal ablation of recurrent lung cancer in patients post radiotherapy. A case series review
CT guided thermal ablation of recurrent lung cancer in patients post radiotherapy. A case series review Poster No.: R-0106 Congress: 2014 CSM Type: Scientific Exhibit Authors: S. Gray; BRISBANE/AU Keywords:
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationNorthern Suburbs Clinic for Lung Cancer (NSCLC): Targeting Lung Cancer
Northern Suburbs Clinic for Lung Cancer (NSCLC): Targeting Lung Cancer Page 1 Phuong Tran (Rad Onc) Lung Cancer Most common cause of cancer related deaths in Australia 19% of all cancer deaths Survival
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationNew Radiation Treatment Modalities in the Treatment of Lung Cancer
New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions
More informationClinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology
Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More informationMedically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes
Review Article Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes J. Isabelle Choi Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
More informationInnovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D.
Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy Sue S. Yom, M.D., Ph.D. Disclosures Genentech: advisory, research support ImClone: research support Plexxikon: research support
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationRFA of Tumors of the Lung: How and Why. Radiofrequency Ablation. Radiofrequency Ablation. RFA of pulmonary metastases. Radiofrequency Ablation of Lung
RFA of Tumors of the Lung: How and Why Radiofrequency Ablation of Lung Ernest Scalzetti MD SUNY Upstate Medical University Syracuse NY FDA WARNING: Off-label use of a medical device Radiofrequency Ablation
More informationAmerican Society of Clinical Oncology All rights reserved.
Stereotactic Body Radiotherapy for Early Stage Non- Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-based Guideline Introduction
More informationStereotactic body radiotherapy (SBRT) has been increasingly
original article Central versus Peripheral Tumor Location Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non Small-Cell Lung Cancer Henry S. Park,
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationStereotactic ablative radiotherapy (SABR) for early-stage lung cancer. Professor Suresh Senan VU University Medical Center Amsterdam, The Netherlands
Stereotactic ablative radiotherapy (SABR) for early-stage lung cancer Professor Suresh Senan VU University Medical Center Amsterdam, The Netherlands Disclosures Research support: Varian Medical Systems
More informationResponse Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer
Original Article PROGRESS in MEDICAL PHYSICS Vol. 26, No. 4, December, 2015 http://dx.doi.org/10.14316/pmp.2015.26.4.229 Response Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer Ji
More informationInnovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy
Innovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy Hak Choy, MD Professor and Chairman Department of Radiation Oncology Univ. of Texas Southwestern Dallas Texas Primary
More informationInnovations in Radiation Therapy, Including SBRT, IMRT, and Proton Beam Therapy
Slide 1 Innovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy Hak Choy, MD Professor and Chairman Department of Radiation Oncology Univ. of Texas Southwestern Dallas Texas
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationStereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters
Original Article Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD,* Ellen D. Yorke, PhD,* Amanda Foster, BA,* Meier Hsu, MS,* Zhigang Zhang, PhD,* Fan Liu,
More informationSBRT & WEDGE RESECTION ARE EQUIVALENT THERAPIES FOR EARLY STAGE LUNG CANCER AND OLIGOMETASTATIC DISEASE
& WEDGE RESECTION ARE EQUIVALENT THERAPIES FOR EARLY STAGE LUNG CANCER AND OLIGOMETASTATIC DISEASE David Rice AATS/STS GENERAL THORACIC SURGERY SYMPOSIUM, APRIL 26, 2015 Disclosure Olympus America, Inc.,
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationDose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed
Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer
More informationApplicazione Clinica: Polmone
Applicazione Clinica: Polmone Andrea Riccardo Filippi Dipar5mento di Oncologia Università di Torino A technique for delivering external beam radiotherapy i. with a high degree of accuracy to an extra-cranial
More informationUpdates in Thoracic Oncology
Updates in Thoracic Oncology Dr. Sameena Uddin MD FRCSC Thoracic Surgical Oncologist Division Head, Thoracic Surgery Trillium Health Partners 1 Faculty/Presenter Disclosure Faculty: Dr. Sameena Uddin MD,
More informationSABR. Outline. Stereotactic Radiosurgery. Stereotactic Radiosurgery. Stereotactic Ablative Radiotherapy
CAGPO Conference October 25, 2014 Outline Stereotactic Radiation for Lung Cancer and Oligometastatic Disease What Every GPO should know Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationRadiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer
Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationUniportal video-assisted thoracoscopic surgery segmentectomy
Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationThoracic complications post stereotactic body radiotherapy (SBRT) for lung cancer - what the radiologist needs to know
Thoracic complications post stereotactic body radiotherapy (SBRT) for lung cancer - what the radiologist needs to know Poster No.: C-1700 Congress: ECR 2014 Type: Educational Exhibit Authors: G. E. Khanda,
More informationSurvey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea
pissn 1598-2998, eissn 2005-9256 Original Article https://doi.org/10.4143/crt.2016.219 Open Access Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung
More informationPercutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer Baodong Liu, Lei Liu, Mu Hu, Kun
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationLung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
More information20. Background. Oligometastases. Oligometastases: bone (including spine) and lymph nodes
125 20. Oligometastases Background The oligometastatic state can be defined as 1 3 isolated metastatic sites, typically occurring more than six months after successful treatment of primary disease. 1 In
More informationCase Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2
Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2 Case 79 yo M with hx of T3N0 colon cancer diagnosed in 2008 metastatic liver disease s/p liver segmentectomy 2009
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationThoracoscopic Lobectomy: Technical Aspects in Years of Progress
Thoracoscopic Lobectomy: Technical Aspects in 2015 16 Years of Progress 8 th Masters of Minimally Invasive Thoracic Surgery Orlando September 25, 2015 Thomas A. D Amico MD Gary Hock Professor of Surgery
More informationThe Role of Radiation Therapy in the Management of Lung Cancer
The Role of Radiation Therapy in the Management of Lung Cancer WILSON APOLLO, MS, CTR, RTT WHA CONSULTING OCTOBER 4, 2018 Objectives Describe and explain how a linear accelerator (Linac) works, and list
More informationsurgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More information